Department of Justice July 19, 2023 – Federal Register Recent Federal Regulation Documents
Results 1 - 3 of 3
Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction
On March 6, 2023, the Drug Enforcement Administration published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin- 4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as brorphine), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. In an amendatory instruction, the document incorrectly designated certain paragraphs. This document corrects that instruction.
Bulk Manufacturer of Controlled Substances Application: VICI Health Sciences, LLC
VICI Health Sciences, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.